IL6 and neoplasm: Treatment with trastuzumab induces repolarization of M2 to M1 macrophages, promoting an anti-tumor immune response through the release of pro-inflammatory cytokines such as tumor necrosis factor (TNF)-α and interleukin (IL)-6 [29, 30].